There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926
Recruiting
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 3 years after enrollment. Additional participant data will be collected from the time the indiv... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
03/26/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Limb-girdle Muscular Dystrophy
Register for Updates
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493
Recruiting
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Register for Updates
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029
Recruiting
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Register for Updates
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
NCT04566666
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Site # 03, Dallas, Texas
Conditions: Moderate to Severe Plaque Psoriasis
Register for Updates
Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation
NCT04715958
Recruiting
This phase II/III trial studies if contrast-enhanced ultrasounds using a contrast dye, perflutren lipid microspheres (Definity), can predict the response to chemotherapy by estimating the pressure in the cancer in patients with breast cancer that has spread to nearby tissues and lymph nodes (locally advanced). The efficacy of cancer therapy is affected by the pressure in the cancer. Definity is a contrast dye used to create better images during ultrasounds. The purpose of this trial is to determ... Read More
Gender:
Female
Ages:
21 years and above
Trial Updated:
03/25/2024
Locations: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Register for Updates
Outcomes of Focal Ablation for Prostate Cancer
NCT05478694
Recruiting
This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.
Gender:
Male
Ages:
Between 18 years and 90 years
Trial Updated:
03/25/2024
Locations: UTSW, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315
Recruiting
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Register for Updates
Fractional Radiofrequency for Reduction of Surgical Scar Formation
NCT05897723
Recruiting
Safety and Efficacy of Fractional Radiofrequency for the Reduction of Surgical Scar Formation
Gender:
Female
Ages:
Between 21 years and 75 years
Trial Updated:
03/25/2024
Locations: UT Southwestern Medical Center, Department of Plastic Surgery, Dallas, Texas
Conditions: Surgical Incision
Register for Updates
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
NCT05948657
Recruiting
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
Gender:
Male
Ages:
Between 18 years and 90 years
Trial Updated:
03/25/2024
Locations: UT Southwestern, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2024
Locations: FutureSearch Trials of Dallas, LP, Dallas, Texas
Conditions: Generalized Anxiety Disorder
Register for Updates
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Texas Health Presbyterian Hospital Dallas, Dallas, Texas +1 locations
Conditions: Mitral Valve Regurgitation
Register for Updates
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
NCT04703842
Recruiting
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/24/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
Register for Updates